J&J wins FDA approval for facial filler

J&J received FDA approval to market Evolence, the first offering by a major U.S. pharmaceutical manufacturer in the dermal filler market. The injectable collagen, from J&J's new aesthetics group, is a porcine-derived collagen filler recommended for treating facial wrinkles, especially deep facial wrinkles and folds, and will compete with big sellers Juvaderm (Allergan) and Restalyne (Medicis). Success will likely depend on whether consumers prefer a pig-derived product or a synthetic one, as well as the likelihood of consumers to hit the luxury cosmetic bar to drown their sorrows in challenging economic times. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.